Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)
Yükleniyor...
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
BioMed Central Ltd
Erişim Hakkı
Attribution 4.0 International
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2.
Açıklama
Anahtar Kelimeler
Colon Cancer, Fluouracil, Rechallenge, Regorafenib, Survival, Third-Line Treatment
Kaynak
BMC Cancer
WoS Q Değeri
Scopus Q Değeri
Q1
Cilt
24
Sayı
1
Künye
Şenocak Taşçı, E., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atcı, M. M., Sakin, A. ... Bozkurt, M. (2024). Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5). BMC Cancer, 24(1). https://dx.doi.org/10.1186/s12885-024-11863-0
